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The human  a  and fl interferon  (IFN) gene family is even more complex than  has 
been  generally  appreciated.  Human  interferons  are  classified  as  a  (leukocyte),  fl 
(fibroblast),  and  y  (immune)  mainly on  serologic  grounds  (1).  Several  investigators 
(2-7)  have  cloned  and  characterized  at  least  8  distinct  cross-hybridizing  species  of 
IFN-a cDNA and  a  set of up to  16 cross-hybridizing  IFN-a genes and  pseudogenes. 
These genes do not have introns (3, 8), are localized to human chromosome 9  (9), and 
appear to correspond to mature polyadenylated  mRNA  of length -0.8-1.4  kilobases 
(kb). These are collectively referred to by us as IFN-as mRNA  (I0,  i I). We recently 
described a second heterodisperse set of translationally  active IFN-a mRNA  of length 
1.6-3.5  kb  (peak activity  at  1.8  kb),  designated  IFN-aL, which  code  for interferons 
that  are serologically  of the a  type, but  that  do  not  appear  to cross-hybridize  with 
as-specific DNA probes  (10,  11).  Several investigators have also described  the molec- 
ular cloning and  characterization  of a  single species of human  IFN-fl cDNA  ("/~1") 
(12)  derived from poly(I), poly (C)-induced  diploid human  fibroblasts  (I 3-19).  Char- 
acterization of the human chromosomal DNA indicates that there exists a single gene 
corresponding  to  IFN-fll  that  does  not  have  introns  (20-24)  and  that  can  also  be 
localized  to human chromosome 9  (9).  Nevertheless,  earlier results of genetic experi- 
ments with somatic cell hybrids had indicated  that human IFN-fl genes were located 
on  human  chromosomes  2,  5,  and  9  and  that  the  presence  of any  of these  human 
chromosomes alone was sufficient  for the expression of human  IFN-fl in somatic cell 
hybrids  (25-30).  However, the results of these somatic cell hybrid experiments  have 
been controversial. On the one hand, Slate and Ruddle  (27, 28) obtained evidence for 
the involvement of chromosomes 2, 5, and 9 in IFN-fl production,  while, on the other 
hand,  Meager  and  his colleagues  (29,  30)  concluded  that  chromosome  9  alone was 
involved in IFN-fl production.  The latter  investigators were unable to find evidence 
to implicate chromosomes 2 or 5, although  low levels of human  IFN production were 
observed in somatic cell hybrids lacking chromosome 9. Data presented in the present 
report indicate that the human  IFN-fl system is quite complex and that the chromo- 
somal localization controversy can be resolved. 
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Materials and Methods 
We prepared polyadenylated IFN mRNA by inducing confluent cultures of FS-4 cells and 
of several  human-mouse somatic cell hybrids with poly(I), poly(C) (P.-L.  Biochemicals,  Inc., 
Milwaukee, WI) and cycloheximide (Calbiochem-Behring Corp., American Hoechst Corp., San 
Diego, CA)  for 4 h, extracting either the total cellular or the cytoplasmic RNA, followed  by 
poly(U)-Sepharose  (Pharmaeia  Fine  Chemicals,  Div.  of Pharmacia  Inc.,  Piscataway,  N  J) 
chromatography (12, 34, 35). A small aliquot (usually, 2/zl out of 25 pl) of each preparation has 
been first assayed for IFN mRNA activity using the Xenopus oocyte assay (12, 34, 35). Suitable 
mRNA  samples  (10-75  #g)  are  mixed  with  marker a2P-labeled  HeLa  cytoplasmic RNA, 
denatured in  12.5 mM CHaHgOH (in 45-/~1 volume), and analyzed by electrophoresis  through 
a 2% agarose-10  mM CHnOH tube gel (11, 12, 36, 37). Thus, RNA electrophoresis is carried 
out  under  stringent  denaturing  conditions.  Because  marker  RNA  species  are  located  by 
Cerenkov counting of the same set of gel slices from which IFN mRNA is subsequently eluted 
(recovery, 50-80%), there is little or no ambiguity in relating the observed IFN mRNA to the 
marker RNA species used. The RNA length estimates in nucleotides for each observed species 
of IFN-fl mRNA are indicated in each experiment. The IFN products synthesized by Xenopus 
oocytes microinjected with ~40%  (2 pl out of 5 #1) of each gel-selected  mRNA fraction have 
been assayed using the conventional semi-micro cytopathic effect inhibition assay with human 
trisomy 21 cells of the GM2504 or GM2767 strain (obtained from the Human Genetic Mutant 
Cell  Repository, Camden,  N  J)  as  cell  substrate  and  with  vesicular stomatitis  virus  as  the 
challenge virus. Ordinarily, we can clearly detect IFN at a concentration of 2 reference U/ml 
in  the oocyte incubation  medium.  Routinely,  ~60%  of each  RNA  fraction is available for 
additional  studies.  All of the oocyte IFN products tested and  described in  this article were 
completely neutralized by an anti-IFN-fll antiserum (raised  by Dr. Y. H. Tan, University of 
Calgary, Canada, against homogeneous human IFN-fll protein) and none of those tested by an 
anti-IFN-et antiserum (obtained from Dr. E. A. Havell, Trudean Institute, Saranac Lake, NY). 
Results 
We  recently  detected  two  distinct  species  of  translationally  active  (in  Xenopus 
oocytes) IFN-fl mRNA in polyadenylated RNA preparations derived from poly(I). 
poly(C)-induced  human  diploid  fibroblasts  (FS-4  strain)  (12).  The  mRNA species 
were resolved by electrophoresis of RNA  under  stringent  denaturing  conditions  in 
agarose-CHaHgOH tube gels.  IFN-fll  (which  corresponds  to the  Knight-Taniguchi 
protein and cDNA sequence)  (14,  31) is of length ~0.9 kb and IFN-fl2 of length ~ 1.3 
kb. Although IFN-fla and IFN-fl2 mRNA code for IFN proteins that are neutralized 
by anti-IFN-fll antisera, their nucleic acids do not cross-hybridize even under relaxed 
hybridization  conditions  (12).  Similar  observations  have  also  been  described  by 
Weissenbach and his colleagues (32). 
Noncoordinate Expression of lFN-fl mRNA.  After the discovery of human IFN-fll and 
f12 mRNA in poly(I).poly(C)-induced FS-4 cells, we proceeded to investigate various 
experimental conditions that might influence the expression of the two mRNA species. 
These studies led to the observation that different derivatives of the FS-4 cell strain 
can consistently express grossly different relative amounts of IFN-fll and f12 mRNA 
after  induction  with  poly(I).poly(C)  (Fig.  1).  Most  of our  previous  experiments 
dealing with the induction of IFN-fl by poly(I), poly(C) in cultures of diploid human 
fibroblasts (34-38) were carried out using a batch of FS-4 cells obtained from Dr. Jan 
Vil~ek (New York University School of Medicine)  in  1973.  We have already shown 
(12)  that several different IFN mRNA preparations derived  from these cells consist 
mainly of IFN-fl2. Fig.  1 A  is another example of the IFN-fl mRNA profile in these 
cells after induction  ("f12 phenotype")  (range of RNA length  estimates  1,241-1,443 
nucleotides;  mean,  1.3 kb). A second batch of FS-4 cells obtained from Dr. Vil~ek in 746  HUMAN fl INTERFERON GENES 
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FIG.  1.  Noncoordinate expression of IFN-fl mRNA in poly(I).poly(C)-induced FS-4 cells. Con- 
fluent cultures of FS-4 cells grown in Eagle's MEM supplemented with 10% bovine serum in 150- 
mm Falcon plastic  petri dishes (Falcon Labware, Div. of Becton, Dickinson  & Co., Oxnard, CA) 
were induced with poly(I)- poly(C) (30/~g/ml) and cycloheximide (50 btg/ml) in 10 ml Eagle's MEM 
for 4 h, the cells harvested  by trypsinization, polyadenylated RNA prepared by poly(U)-Sepharose 
chromatography of the extracted cellular RNA, appropriate amounts of the poly(U)-selected  RNA 
(10-50 vg) mixed with S2p-labeled HeLa cytoplasmic RNA, denatured in 12.5 mM CHaHgOH for 
5-10 rain at room temperature in a 45-/~1 volume, and then electrophoresed  through a 2% agarose- 
10-mM CHzHgOH tube gel, using procedures that have been described earlier (11, 12, 36, 37). IFN 
mRNA eluted from pools of adjacent gel slices (two l-ram slices/pool) was detected by microinjection 
of 2 #1 of each RNA sample (of 5 p.1) into Xenopus oocytes (10-15 oocytes in 0.2 ml Barth's medium 
incubated for 24-48 h), followed by determination of the IFN titer in the incubation medium (1 I, 
12, 37, 42, 43), using GM2504 or GM2767 cells and vesicular stomatitis virus as the challenge virus. 
IFN titers (0) are expressed in terms of the 69/19 reference standard. The lengths in nucleotides of 
the observed IFN mRNA species are derived from the migration of marker 28 S, 18 S, 5 S, and 4 S 
RNA ((3) in the same tube gel (12) and are indicated next to each peak. The IFN mRNA profile in 
RNA from induced cultures derived  from the 1973 batch of FS-4 ceils and that in RNA from the 
1975 batch are indicated in panels A (45 p.g RNA) and B (10 #g RNA), respectively. 
the fall of 1975 was found to express mainly IFN-fla (Fig.  1 B, "ill phenotype")  (range 
of RNA length estimates 861-1,019 nueleotides; mean, 0.9 kb). These two batches of 
cells were found to express the appropriate f12 or fll phenotype in experiments over a 
period of several  months  (data  not shown).  These  data suggest  that  the two  IFN-fl 
mRNA  species can be expressed  in a  noncoordinate manner. 
Further Heterogeneity oflFN-fl mRNA Species.  Figs.  2  and 3  reveal further heteroge- 
neity ofIFN-fl mRNA  species derived from some batches of FS-4 cells. Fig. 2 illustrates 
three  different  preparations  from  induced  FS-4  cells  that  display  IFN-fl  mRNA 
activity in RNA  of length ~1.8  kb  (close to  the  18  S  marker).  The  data  in Fig.  2B 
clearly demonstrate  that  the  long IFN-fl mRNA  described  in  Fig.  2A,  which  runs 
close to the  18  S  marker, which in turn is included in the same agarose-CHaHgOH 
tube  gel,  is not  an aggregation  artifact.  For convenience, we  refer  to  the  species  of 
IFN-fl mRNA  of length of ~  1.8 kb (range,  1,628-1,939 nucleotides; mean,  1.8 kb) as 
IFN-fla  rnRNA  (37).  Fig.  3  illustrates  three  different  preparations  of IFN  mRNA 
obtained from poly(I), poly(C)-induced FS-4 cells that exhibit IFN mRNA  of length A.  D.  SAGAR,  P.  B.  SEHGAL,  D.  L.  SLATE,  AND  F.  H.  RUDDLE  747 
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Ftc.  2.  Human  IFN-fl3 mRNA.  IFN  mRNA  (0)  profile  in  polyadenylated RNA  (30-50  #g) 
derived from FS-4 cells induced with poly(I).poly(C) in  the presence of eycloheximide and 5,6- 
dichloro-1-fl-D-ribofuranosylbenzimidazole  (DRB)  for 4 h (panels A, B, C) or with poly(I), poly(C) 
alone (panel D). Panels A and D represent total cellular polyadenylated RNA preparations, whereas 
panel C is a cytoplasmic polyadenylated RNA preparation. 60% of the RNA eluted from gel slices 
indicated in panel A by the horizontal bar were pooled, denatured a second time in CH3HgOH, 
and reelectrophoresed  through a second agarose-CH3HgOH tube gel (panel  B). +, indicates that 
oocyte IFN products derived from the 1.7-1.8 kb RNA, shown in panels C and D, were neutralized 
by an anti-IFN-fl]  antiserum. The IFN titers in the absence of antiserum were 8 and  16 reference 
U/m!, whereas the residual titers after mixing with anti-IFN-fl] antiserum were <2 and <2 reference 
U/ml for the products of the long mRNA in panels C and D, respectively.  Antiserum controls are 
illustrated in Table I. Marker RNA (©). 748  HUMAN #  INTERFERON  GENES 
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FIG.  3.  Human  IFN-#4  mRNA.  IFN  mRNA  (0)  profile  in  cellular  (panels  A  and  B)  and 
cytoplasmic (panel C) polyadenylated RNA (30-60 p,g) derived from FS-4 cells induced with poly(I) • 
poly(C) in the presence of cycloheximide (panel A includes DRB). +, indicates that the oocyte IFN 
products derived from the 0.6-0.7 kb mRNA shown in panels A and C were neutralized by an anti- 
IFN-flx  antiserum. The IFN  titers in  the absence of antiserum were 32  and  32  reference U/ml, 
whereas the residual titers after mixing with anti-IFN-/~l antiserum were <2 and <2 reference U/ml 
for the products of the shortest IFN mRNAs shown in panels A  and C, respectively. Antiserum 
controls are illustrated in Table I. Marker RNA (O). 
between  0.6  and  0.7  kb.  For  convenience,  we  refer  to  this  IFN-#  mRNA  (range, 
614-684  nucleotides;  mean, 0.65 kb) as IFN-/~4 mRNA. 
The  range of RNA  length  estimates  for the individual  IFN-]3 mRNA  observed  in 
numerous  independent  experiments  over a  period  of 2  yr is  nonoverlapping  and  in 
each  instance corresponds  to one fraction or a  2-mm distance  out of 80-90  mm  in a 
gel (distance from top of gel to 4 S marker RNA). Although our overall RNA recovery 
is in the range of 50-80%  from one gel to the next, the extent  of RNA recovery from A. D. SAGAR, P.  B. SEHGAL, D. L. SLATE, AND F.  H. RUDDLE  749 
gel slices derived from the same gel is rather uniform. Because we mix in raP-labeled 
HeLa cytoplasmic RNA with IFN mRNA  preparations  before the gel run, we can 
directly monitor RNA  recoveries across each gel.  We are  thus  able  to exclude the 
possibility that the data in Figs.  1 A, 2 D, 3 B, 3 C, and 4 C  result from differences in 
RNA recovery. 
With the discovery that translationally active human IFN-fl mRNA are heteroge- 
neous in RNA length and the realization that the expression of these mRNA can be 
consistently noncoordinate, it was apparent that we had the theoretical elements for 
the  resolution  of the  chromosomal  localization  controversy in  hand  (25-30).  The 
somatic  cell  hybrids  analyzed  by  Meager  et  al.  (29,  30)  might  have  consistently 
expressed mainly IFN-fll derived from chromosome 9, while those analyzed by Slate 
and  Ruddle  (27,  28)  might  have expressed additional  IFN-fl mRNA  derived from 
other chromosomes. We therefore proceeded to carry out gel analyses of IFN mRNA 
preparations  derived from poly(I).poly(C)-induced human-mouse somatic cell  hy- 
brids. 
Human  Interferon mRNA  in  Induced  Human-Mouse  Somatic  Cell  Hybrids.  A  series  of 
human-mouse somatic cell hybrids that had been extensively investigated in the past 
for human interferon production and whose karyotype had been characterized were 
selected for study (Table I)  (27,  28).  These hybrids contained different combinations 
of human  chromosomes 2,  5,  and  9  and  were known  to  be inducible  by poly(I). 
poly(C) for human IFN-fl production in cell culture  (27,  28).  Appropriate cultures 
were  induced  with  poly(I).poly(C)  in  the  presence of cycloheximide and  cellular 
polyadenylated RNA prepared by poly(U)-Sepharose chromatography. An appropri- 
ate aliquot (2/~1 out of 25/~1) was assayed in Xenopus oocytes for IFN mRNA activity. 
Poly(I).poly(C) induction  of the  parental  murine cells  fails  to  induce any IFN or 
mRNA coding for IFN active on human cells (27, 28, 40). Table I shows that not only 
did many of the hybrids express human IFN mRNA activity, but also that all of the 
detectable IFN activity was of the fl type. Thus, all of the hybrids listed in Table I 
express human IFN-~ mRNA, even though most of them lack human chromosome 9. 
Similar results have also been obtained by Pitha et al.  (40).  It was rather surprising 
to find that BDA 17b 17/DpT-2, a hybrid that appears to lack human chromosomes 
2, 5, and 9, expressed IFN-fl mRNA activity. Many of the IFN-/~ mRNA preparations 
listed in Table I  were then subjected to analysis by agarose-CHaHgOH gel electro- 
phoresis. Fig. 4 summarizes some of the results obtained. 
Gel Electrophoresis of IFN mRNA from  Somatic  Cell Hybrids.  Fig.  4A  describes  the 
IFN-fl  mRNA  species  observed  in  a  hybrid  that,  against  a  murine  background, 
contains  a  complex  human  chromosome  involving  translocated  pieces  of human 
chromosomes 9,  11, and X  (28). This hybrid expresses an  IFN-fl mRNA  of length 
~0.9 kb. This result is consistent with the assignment of IFN-flx to human chromosome 
9 (9). 
Fig. 4B and C  describe two independently derived hybrids that have been exten- 
sively studied  by isozyme patterns  and  karyotype analyses  and  are known  to lack 
human chromosome 9. Nevertheless, both these hybrids express an IFN-fl mRNA of 
length 0.9 kb. A  derivative of AIM15aB1  that  has also been extensively verified to 
lack human chromosome 9 (Fig. 4 D) also expresses an IFN-fl mRNA of length 0.9 kb. 
Furthermore,  a  sister  clone  of AIMI5aB1  (AIM15aA3)  and  a  second  batch  of 
BDAI0a3 cells have been found to be devoid of IFN-fll-specific DNA,  and transla- 750  HUMAN  /~  INTERFERON  GENES 
TABLE  I 
Human IFN mRNA  in poly (I) .poly (C)-induced Human-Mouse Somatic Cell Hybrids 
Human-mouse hybrid  Human chromosome 
composition 
Residual interferon titer in oocyte 
medium 
No anti-  Anti-o:  Anti-]~l  serum 
reference U/ml 
29/21-30b SR  X, 9,  11  48, 32  ND*  <4 
AIM 15aB1  2+5+9-  48, 32  ND  <4 
48, 16  32  <4 
AIM 15aB 1/DpT  2÷5-9  -  128, 64  ND  <4 
BDA 10a3  2*5-9- (10% 5  ÷)  32, 32  ND  <4 
16, 32  64  <4 
BDA 10a3/DpT  2+5-9  -  12, 32  32  <4 
BDA 17b17  2+5+9  +  64, 128  ND  <4 
16, 32  32  <4 
8,  12  12  ~3 
BDA 17b17/DpT-2  2-5-9-  64  64  <4 
16, 12  24  63 
Antiserum controls 
IFN-O: (leukocyte)  >256  4  >256 
IFN/~ (fibroblast)  128  128  <2 
Batches of appropriate human-mouse somatic cell hybrids were grown to confluence either 
in 850-cm  2 Coming plastic roller bottles (8-10 per batch) or in  150-ram  Falcon plastic 
petri dishes (60-100 per batch) in Eagle's MEM supplemented with 5-10% fetal bovine 
serum and then induced with poly(I), poly(C) (100 ~tg/ml)  and cycloheximide (50/xg/ml) 
for 4  h. The cells  were  harvested by trypsinization, and cellular polyadenylated RNA 
was  prepared  (34,  35).  Each  mRNA  sample  (35-50 btg RNA)  was  dissolved  in  25  #1 
sterile distilled water, and a  2-btl aliquot was assayed for IFN mRNA activity using the 
Xenopus oocyte assay (12). The serology  of IFN in oocyte incubation medium was verified 
by the addition of 10/~1 of anti-IFN-o: antiserum (obtained from Dr. E. A. Havell, Trudean 
Institute, Saranac Lake, NY) or 2 lal of an anti-IFN-/~l antiserum (obtained from Dr. Y. H. 
Tan, University of Calgary, Canada), as described earlier (12, 34, 37).  Human leukocyte 
IFN (IFN-a) and human fibroblast IFN  (IFN-/~) samples were obtained from Dr. W. E. 
Stewart II and Dr. W. A. Carter, respectively. Each IFN titer represents a separate assay 
(42, 43), and each data line represents a different RNA preparation. The human chromo- 
some composition of each hybrid was determined to be as fol[ows: 29[21-30bSR: "X, 9, i I 
translocated chromosome;" AIM15aBI:  1,2,5,7,11,12,13,14,15,17,18,20,21,X;  AIM15aB1/ 
DpT:  1,2,7,11,12,13,14,15,17,18,20,21,X;  BDA 10a3:2,6,10,12,13,16,18,20,X,5  at 10% and 
a low frequency (<20%) of 3,4,8,11,17;  BDA 10a3/DpT: 2,6,8,10,11,12,13,16,17,20,X  and 
a low frequency (<20%) of 3,11; BDA 17b17:  1,2,4,5,6,9,12,13,14,16,18,20,21,X  and trace 
of 3; BDA 17bl7/DpT-2: 4,13,21. 
* Not done. 
tionally  active  IFN-/3  mRNA  preparations  derived  from  these  particular  hybrids 
failed to hybridize with IFN-/31 eDNA  probes  (40).  Similarly, a  second sister clone of 
AIM15aB1  (AIM15aA1)  and  another  batch  of  BDA10a3  cells  were  found  to  be 
devoid of IFN-al-specific DNA  sequences that are also known  to map  to chromosome 
9  (9,  44).  This  excludes  the  possibility  that  aberrant  fragments  of chromosome  9 
containing  the IFN-/3a  gene are  retained  in the AIM15a  and  the BDA10a3  series of 
human-mouse  hybrids. 
Because from Table  I, we know that all of the IFN  mRNA  species described in Fig. 
4B, C,  and  D  are of the/3  type,  for convenience, we  refer to the 0.9  kb mRNA  that 
we are unable  to assign to chromosome  9  as IFN-/3s mRNA.  Thus,  in a  formal sense, A.  D.  SAGAR,  P.  B.  SEHGAL,  D.  L.  SLATE,  AND  F.  H.  RUDDLE  751 
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FZG.  4.  IFN-p mRNA  (0)  species  in a  selection of human-mouse somatic cell hybrids induced 
with poly(I).poly(C)  in the presence of cycloheximide.  Appropriate preparations  (35-50 #g)  of 
translationally active IFN-~ mRNA illustrated in Table I were analyzed by agarose-CH3HgOH gel 
electrophoresis,  mRNA eluted from gel slice pools was dissolved in 2 #1 water, and the entire sample 
was assayed by microinjection into Xenopus oocytes.  Panel A, 29/21-30bSR cells containing the X, 
9,  11 translocated chromosome; panel B, AIM 15a B1:2+5+9-;  panel D, its diptheria toxin-treated 
derivative (AIM  15aB1/DpT),  which is  therefore 2+5-9-;  and  panel C,  BDA  10a3,  designated 
2+5-9  -  by isozyme pattern.  10% of the cells  in BDA  10a3 contain chromosome 5, as assayed by 
diptheria  toxin-mediated  cell  killing  and  chromosome  analyses;  panel  E,  the  diptheria-toxin 
derivative, BDA 17bl7/DpT-2, which is 2-5-9-. Marker RNA ((3). 752  HUMAN  /~  INTERFERON  GENES 
the 0.9 kb IFN-/~ mRNA peak observed in preparations from induced human diploid 
fibroblasts (12) could represent IFN-/~1 or/~5 or both. 
The data summarized in Fig. 4 are consistent with the tentative assignments of four 
of the five observed IFN-/~ mRNA to human chromosomes 2, 5, and 9. Those in Fig, 
4 A are consistent with the assignment of IFN-/?x to chromosome 9. Fig. 4 B shows that 
a hybrid that is 2+5+9 -  expresses IFN-/~2 and/~5, whereas its diptheria toxin-treated 
derivative that has lost chromosome 5 (Fig. 4 D) expresses only IFN-/35. Thus, data in 
Fig. 4 B and D  are consistent with the assignment of IFN-~2 to chromosome 5.  Fig. 
4C represents an independent confirmation of this assignment. Approximately 10% 
of BDA 10a3 ceils, which as a population are 2+5-9  -  (by isozymes), contain chromo- 
some  5  (by diptheria  toxin  cell-killing and  by chromosome analyses).  These cells 
express a  small amount  of IFN-~2  (Fig.  4 C).  The data in  Fig.  4 C  and  D  are also 
consistent with the assignment of IFN-/~3 and/~  to chromosome 2. In addition, the 
data in Fig. 4 E suggest that the human IFN-/~ system might be even more complex. 
A  human-mouse hybrid (BDA  17bl7/DpT-2), which appears to lack human chro- 
mosomes 2, 5, and 9, expresses IFN-~ mRNA of length -  1 kb. The karyotype of this 
hybrid is presently under detailed investigation. Perhaps Fig.  4E provides the first 
indication  of a  sixth  species  of human  IFN-/3  mRNA  that  may  derive  from  a 
chromosome other than 2, 5, or 9. 
These data clearly show that  IFN-]3 genes are located on at least  three different 
human chromosomes. However the particular assignments are still tentative and will 
need to be confirmed by the molecular cloning of the individual IFN-/~ mRNA species 
and by the chromosomal mapping of these genes using recombinant DNA procedures. 
At the present time, we cannot exclude the possibility that IFN-fl3 and/3~ derive from 
the same gene, nor can we exclude the possibility that IFN-/~4 derives from one of the 
other IFN-/~  genes. 
Discussion 
Our studies have provided a basis for the resolution of the chromosomal localization 
problem that has existed in the IFN-B field for the last 7 yr. Briefly we consider that 
the observations reported by previous investigators  (25-30)  were essentially correct 
but that the earlier interpretations of the then available data did not fully recognize 
the complexities involved in the structure and expression of human IFN-/~ genes. The 
IFN-/~ gene family, of which only IFN-/~I has been cloned and characterized convinc- 
ingly (13-24), is dispersed in the human genome. We have shown earlier (12) that an 
IFN-/~I  cDNA  probe  does  not  cross-hybridize IFN-B2  mRNA,  even  under  rather 
relaxed hybridization conditions. The failure to pick up chromosomal DNA clones 
other than IFN-/~a by screening human DNA gene banks with IFN-]~a cDNA probes 
(20-24, 33) suggests that the other dispersed IFN-/~ genes do not cross-hybridize IFN- 
Bx DNA, even though they code for proteins that  are neutralized by an antiserum 
raised  against  homogeneous  IFN-/~I  protein.  Furthermore,  it  appears  that  these 
dispersed genes can be expressed independently of each other. Though the IFN-/~I is 
a gene without introns (20-24, 33), there is suggestive evidence that IFN-]~2 might be 
a gene with introns (41, and Michel Revel, personal communication). It is clear that 
a great deal still remains to be learned about the structure and expression of human 
IFN-B genes. 
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cell culture? The fact that attention was focused on somatic cell hybrids described in 
Table  I,  mainly  because  they  were  found  to  produce  IFN-fl  in  cell  culture  after 
induction with poly(I), poly(C) (27, 28), suggests that the answer to this question is in 
the affirmative. Furthermore, in preliminary experiments carried out using FS-4 cells 
known  to exhibit  the f12 phenotype,  we  (P.  B.  Sehgal,  Y.  H.  Tan,  and  colleagues, 
unpublished data) have detected an IFN-fl-specific polypeptide distinguishable by its 
mobility  in  a  polyacrylamide gel  from authentic  IFN-flx in  the  culture  medium  of 
superinduced  FS-4 cells using a  polyacrylamide gel blotting procedure.  It will be of 
interest  to determine  whether  these  different  IFN are  tailored  to represent  specific 
host-defense responses to combat specific situations. 
Summary 
Analysis of human fl interferon  (IFN) mRNA preparations obtained from poly(I) • 
poly(C)-induced human diploid fibroblasts (FS-4) and from several similarly induced 
human-mouse  somatic  cell  hybrids  by electrophoresis  through  agarose-CHaHgOH 
tube  gels  led  to  the  detection  of at  least  five  translationally  active  human  IFN-fl 
mRNA species. The results obtained are consistent with the existence of IFN-fl genes 
on different human chromosomes. Marked cell-dependent variability in the expression 
of these IFN mRNA species was observed. 
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leukocyte (a)  and fibroblast (fl) interferons, respectively. We also thank Mr. Ira Augenzucker 
and Ms. Ann Cunningham for excellent technical assistance. 
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